Watchlist Price Alert

Merus N.V. (MRUS)

NASDAQ: MRUS · Real-Time Price · USD

41.00

-1.77 (-4.14%)

At close: May 09, 2025, 3:59 PM

41.37

0.90%

After-hours: May 09, 2025, 05:26 PM EDT

-4.14% (1D)

Bid	40.9
Market Cap	2.84B
Revenue (ttm)	36.13M
Net Income (ttm)	-215.33M
EPS (ttm)	-3.35
PE Ratio (ttm)	-12.24
Forward PE	-8.94
Analyst	Buy

Ask	48.18
Volume	507,902
Avg. Volume (20D)	754,318
Open	43.00
Previous Close	42.77
Day's Range	40.95 - 43.90
52-Week Range	33.19 - 61.61
Beta	0.95

About MRUS

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol MRUS

Website n/a

Full Company Profile

Analyst Forecast

According to 0 analyst ratings, the average rating for MRUS stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

Stock Forecasts

Earnings Surprise

Merus has released their quartely earnings on May 7, 2025:

Revenue of $26.49M exceeds estimates by $19.01M, with 235.76% YoY growth.

EPS of -1.4 misses estimates by -0.35, with -137.29% YoY decline.

Next Earnings Release

Merus N.V. is scheduled to release its earnings on May 20, 2025, during market hours.
Analysts project revenue of ... Unlock content with Pro Subscription

Why Price Moved

2 months ago

+5.15%

Merus shares are trading higher after the company ... Unlock content with Pro Subscription

3 months ago

-7.75%

Merus shares are trading lower. The company announced a research collaboration and license agreement with Biohaven to co-develop three novel bispecific antibody drug conjugates.

News

2 days ago · zacks.com

Merus N.V. (MRUS) Reports Q1 Loss, Tops Revenue Estimates

Merus N.V. (MRUS) came out with a quarterly loss of $1.40 per share versus the Zacks Consensus Estimate of a loss of $1.16. This compares to loss of $0.59 per share a year ago.

3 days ago · zacks.com

Earnings Preview: Merus N.V. (MRUS) Q1 Earnings Expected to Decline

Merus (MRUS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

1 month ago · seekingalpha.com

Merus: Riding The Bispecific Wave In Oncology

Merus stands out in biotech with its innovative Biclonics and Multiclonics platforms, focusing on bispecific and multispecific antibodies, particularly petosemtamab. Strong financials with $724 millio...

2 months ago · zacks.com

Merus N.V. (MRUS) Reports Q4 Loss, Lags Revenue Estimates

Merus N.V. (MRUS) came out with a quarterly loss of $0.41 per share versus the Zacks Consensus Estimate of a loss of $0.95. This compares to loss of $1.09 per share a year ago.